Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|November 1, 2003
AAO Meeting At-A-Glance
The sunny, southern California city of Anaheim plays host this year tothe 107th annual meeting of the American Academy of Ophthalmology (AAO).The program is being held at the completely renovated Anaheim ConventionCenter and features a new compact format that conveniently consolidatesall of the educational opportunities of subspecialty days and the annualmeeting into 5 days. It begins with subspecialty day meetings on Friday,Nov. 14, and ends with the close of the annual meeting on Tuesday, Nov.18. In addition, a full-day recapping "The Best of the Academy in Spanish"takes place on Wednesday, Nov. 19, from 7:30 a.m. to 5:30 p.m. at the Disneyland'sParadise Pier Hotel.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Eyedaptic launches Eva, an agentic AI visual assistant for patients with retinal disease
2
Eyes on October 2026: AAO and EURETINA highlights, a trio of FDA approvals, and optogenetics takes the spotlight
3
Complement inhibition in GA: Timing, safety, and follow-up
4
October 2026 retina recap: Duravyu stumbles, DAYBREAK delivers, and optogenetics takes the Nobel
5